Shares of Teva Pharmaceuticals (TEVA) are down after Bloomberg reported that the generic drug maker agreed with an Astrellas Pharma subsidiary to settle a pending patent-infringment lawsuit for the Tarceva lung cancer drug.
Pfizer (PFE) and Genentech were also a part of the suit.
Teva shares are down 0.74%, or $0.37, to $48.06.
